Nasdaq
$1.42▲ 0.71%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $630.8MShares out 4.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 8.17Pre-market26.08.17 13:15filedEFFECTOther#●●●#●●●
LEXICON PHARMACEUTICALS, INC.
Lexicon Pharmaceuticals received official effectiveness approval from the SEC for its registration statement on August 14, 2026. This approval allows the company to proceed with the securities offering or capital raising activities outlined in the filing.…more
$1.42+0.71%vs prev closeView filingShare
- 8.6After-hours26.08.07 06:07S-3Offering
LEXICON PHARMACEUTICALS, INC.
렉시콘 파마슈티컬스는 2026년 5월 4일 발행된 워런트의 행사로 인해 발행될 보통주 1,257,856주에 대한 등록 신청서(S-3)를 제출했습니다. 이번 공시는 기존 워런트 보유자인 매도 주주들이 시장 상황에 따라 해당 주식을 매도할 수 있도록 등록하는 절차이며, 회사 측에 유입되는 직접적인 자금 조달은 없습니다.…more
$1.42+0.71%vs prev closeView filingShare - 8.6After-hours26.08.07 05:32S-8Offering
LEXICON PHARMACEUTICALS, INC.
렉시콘 파마슈티컬스는 2026년 4월 30일 주주 승인을 거쳐 기존 주식 보상 계획을 2026년형으로 개편하고, 총 1,700만 주의 신주 발행을 위한 S-8 등록 서류를 제출했습니다. 이번 조치로 2026년형 주식 보상 계획과 비임원 이사 주식 보상 계획에 각각 1,500만 주와 200만 주의 신주가 추가되어, 총 등록 주식 수는 각각 9,200만 주와 620만 주로 증가합니다.…more
$1.42+0.71%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoPre-market26.10.23 21:30#●●●#●●●
Lexicon Pharmaceuticals Updates Phase 3 SONATA-HCM Study Baseline Data
Lexicon Pharmaceuticals released baseline patient characteristics for its Phase 3 SONATA-HCM trial, confirming the study is well-positioned for evaluation. The company exceeded enrollment targets with 542 patients and expects to report topline results in the first quarter of 2027.…more
$1.42+0.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 3d agoPre-market26.10.21 21:30
●●●●●●●● ●●●●● ●●●●●●
Lexicon Pharmaceuticals announced new preclinical study results highlighting the biological benefits of sotagliflozin in treating hypertrophic cardiomyopathy and preventing thrombosis. These findings are preliminary, and investors should await the upcoming Phase 3 trial results for clinical validation.…more
$1.42+0.71%vs prev close - 9.1After-hours26.09.02 05:05
●●●●●●●● ●●●●● ●●●●●●
Lexicon Pharmaceuticals announced that its management will present at three upcoming investor conferences in New York this September. These events serve as platforms for the company to discuss its pipeline and corporate vision with investors.…more
$1.42+0.71%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report